| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.18B | 11.09B | 11.07B | 11.32B | 11.11B | 10.74B |
| Gross Profit | 837.70M | 1.64B | 759.70M | 792.80M | 770.50M | 716.30M |
| EBITDA | 440.10M | 472.00M | 434.90M | 437.30M | 460.60M | 371.00M |
| Net Income | 195.40M | 214.80M | 182.00M | 201.10M | 223.90M | 157.10M |
Balance Sheet | ||||||
| Total Assets | 5.39B | 5.85B | 5.47B | 5.88B | 5.35B | 5.12B |
| Cash, Cash Equivalents and Short-Term Investments | 482.10M | 609.10M | 687.20M | 636.40M | 673.70M | 680.80M |
| Total Debt | 736.50M | 839.80M | 958.20M | 1.01B | 587.10M | 565.60M |
| Total Liabilities | 3.68B | 3.97B | 3.73B | 4.05B | 3.46B | 3.32B |
| Stockholders Equity | 1.65B | 1.82B | 1.69B | 1.76B | 1.81B | 1.74B |
Cash Flow | ||||||
| Free Cash Flow | 287.50M | 321.30M | 340.80M | 237.00M | 338.20M | 289.60M |
| Operating Cash Flow | 322.50M | 362.90M | 393.10M | 321.90M | 393.20M | 325.30M |
| Investing Cash Flow | -65.40M | -75.60M | -116.50M | -511.80M | -147.90M | -103.20M |
| Financing Cash Flow | -252.50M | -364.20M | -185.20M | 180.70M | -239.50M | -113.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | CHF4.15B | 17.59 | ― | 1.88% | -0.71% | -6.12% | |
70 Outperform | CHF3.72B | 19.05 | ― | 4.11% | 2.66% | 2.91% | |
66 Neutral | CHF17.34B | 27.00 | ― | 3.58% | 3.12% | 11.70% | |
65 Neutral | CHF3.80B | 13.95 | ― | 4.41% | -4.68% | -5.79% | |
63 Neutral | CHF20.91B | 20.32 | ― | 4.68% | 6.54% | -10.57% | |
63 Neutral | CHF5.85B | 25.79 | 22.69% | 1.83% | 8.15% | 12.24% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% |
DKSH has appointed Patrik Grande as the new Head of Business Unit Healthcare, succeeding Bijay Singh who will retire in March 2026. Grande, who has over 20 years of experience in the pharmaceutical industry, is expected to leverage his expertise to drive growth and strategic progress in DKSH’s Healthcare division, enhancing the company’s market position and operational capabilities.
DKSH celebrates its 160th anniversary, marking its long-standing presence in Asia since its inception in Japan in 1865. The company has played a significant role in the economic development of the region and continues to strengthen the bilateral trade relationship between Switzerland and Japan. By hosting an ‘Evening of Gratitude’ in Tokyo, DKSH reaffirmed its commitment to the Japanese market and its role as a key player in various industries, including food and beverages, personal care, and pharmaceuticals. The celebration highlighted DKSH’s evolution from its entrepreneurial roots to a global partner, emphasizing its impact on innovation and partnerships.
DKSH has been recognized as an ‘Industry Leader’ in sustainability by the 2025 ISS ESG Corporate Rating, with an improved rating of B- from C+. This achievement highlights DKSH’s strong climate strategy and commitment to reducing its environmental impact, including a significant reduction in CO2 emissions. The company’s focus on business ethics, governance, and employee well-being further supports its sustainability leadership.